Rafi Kabarriti

Rafi Kabarriti practices at The New York Proton Center in New York, New York.

Rafi Kabarriti's NPI, 1811200256, was assigned on July 14, 2010. Rafi Kabarriti graduated from Albert Einstein College of Medicine of Yeshiva University in 2010. Rafi Kabarriti holds New York license 279635-1.

Rafi Kabarriti's primary practice is The New York Proton Center, at 225 E 126th St, New York, NY 10035 in New York County. The practice phone is (646) 968-9064.

Rafi Kabarriti's primary practice is The New York Proton Center in New York, New York. Rafi Kabarriti is also affiliated with Montefiore Einstein Hospital-Moses Campus. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Rafi Kabarriti to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rafi Kabarriti practices. Vendor and product names are available with a free account.

Radiation oncology is Rafi Kabarriti's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Rafi Kabarriti is licensed in New York.

CMS data shows 1,066 Medicare services from Rafi Kabarriti across 14 procedure codes in 2024, for 241 Medicare patients. Medicare paid $183,638 for them.

CMS counts 241 Medicare patients who saw Rafi Kabarriti in 2024. The largest group is 65 to 74, with 110 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 40% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rafi Kabarriti's median patient age at 63, with 42% women.

In 2024, Rafi Kabarriti wrote 478 Medicare Part D claims for 149 patients. 91% of them were for generic drugs. CMS names the drug for 306 of them, across 13 drugs with 11 or more claims each, at $6,237 in total drug cost. In 2023, CMS named 406 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Rafi Kabarriti for performance year 2024, reported as part of a group. CMS lists Rafi Kabarriti as offering telehealth.

Dmand AI links 82 papers to Rafi Kabarriti, published from 2011 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Carcinoma, Hepatocellular, Head and Neck Neoplasms and Liver Neoplasms. Rafi Kabarriti has published most often in Int J Radiat Oncol Biol Phys. Rafi Kabarriti's most frequent co-authors are Shalom Kalnicki, MD, Madhur K. Garg, MD and Keyur J. Mehta, MD.

Dmand AI links Rafi Kabarriti to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Anus Neoplasms and Hypopharyngeal Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 1 general payment to Rafi Kabarriti from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Tempus AI, Inc paid the most, $23.

Rafi Kabarriti graduated from Albert Einstein College of Medicine of Yeshiva University in 2010.